During Bryan Johnson’s Psilocybin trip, he allowed parts of the journey to be light and playful and released the need for data. He listened to leaves cracking under his feet, a sound he had not thought back to since he was a child. He allowed himself to time travel – to daydream.

Then he came back to his life’s mission and measured 249 biomarkers.

That pairing is why the Bryan Johnson Psilocybin experiment deserves a careful read. Johnson is the longevity researcher who built his life around control and precision, and across two sessions he pointed instruments at a Psilocybin experience that almost no one had pointed there before. Blood work. Brain imaging. Continuous glucose monitoring. Thermal imaging. Gut microbiome sequencing. He called it the most quantified psychedelic experience in history. And we loved to watch it.

What came back was a set of numbers that lined up, often strikingly, with what he described feeling.

At Behold, we hold two things at once: deep respect for the ceremonial roots of this medicine, and genuine curiosity about what modern measurement can show us. This is one of the rare moments where both get to speak in the same room.

Why Would a Longevity Researcher Take Psilocybin at All?

Johnson’s whole project is built on measurement, and psychedelics sit awkwardly inside that framework because the experience is subjective by nature.

What moved him was laboratory evidence. In 2025, researchers at Emory University and Baylor College of Medicine published a study in npj Aging that gave the question real weight:

  • Human lung cells treated with psilocin, the active form Psilocybin converts into in the body, took 57 percent longer to reach senescence. Skin cells showed a 51 percent extension.
  • Female mice aged 19 months, roughly 60 to 65 in human years, received a monthly dose of Psilocybin.
  • Ten months later, 80 percent of the treated mice were still alive, compared with 50 percent of the untreated group.

We explored that research, and the wider picture, in can plant medicine support longevity.

Johnson’s question was simple and honest. If something real was happening biologically, it should be measurable in a human body.

So he built a protocol around it: 249 biomarkers spanning brain activity, inflammation, hormones, metabolism, DNA, and cellular aging, measured around two sessions spaced three weeks apart. The doses, roughly 25 mg and then 28 mg of Psilocybin, sat in the range used in modern clinical trials, and both sessions took place under medical supervision with a professional facilitator. These were full doses, not a microdose.

For the second session, he added 136 more measurements, including thermal imaging and continuous brain scans before, during, and after.

He was also openly nervous. His phone filled with warnings about founders who had taken a journey and come back wanting to check out and go off-grid. The fear, he said, wasn’t about mushrooms. It was about identity. It is a fear many high achievers carry into this work, and one we explore in why executives seek plant medicine after success.

What Happened to His Stress Hormones and Inflammation?

During the session, his cortisol spiked sharply. For about three hours after the dose, it ran three to eight times higher than his normal midday level. That is expected: clinical studies have measured a 100 to 300 percent surge 90 to 120 minutes after a Psilocybin dose. By evening, he was back at baseline.

A system that fires hard and then recovers quickly is what a resilient stress response looks like.

The lasting change showed up days later. Five days after the first dose:

  • Morning cortisol had fallen 42 percent.
  • DHEA-S, another marker of adrenal activity, had fallen 45 percent.
  • hs-CRP, a key marker of systemic inflammation, dropped from an already low 0.23 mg/dL to below the 0.15 mg/dL limit of detection.

After the second dose, his hs-CRP read 0.18 mg/dL, still 22 percent below where he started. Chronic, low-grade inflammation is widely considered one of the accelerators of biological aging, so a drop that holds across two sessions is worth noticing.

Johnson put it more simply. His emotions had been a choppy sea, he said, and the Psilocybin smoothed the water to glass. He called the first session one of the best days of his life, and described his state afterward as parasympathetic dominance, the rest-and-digest mode of the nervous system.

Researchers call the calm that can follow a Psilocybin experience the afterglow. His panel suggests the afterglow may have a biochemical signature: a nervous system that has stopped bracing, rather than one that has been sedated.

What Did the Brain Imaging Show About Perception?

This is the part that speaks most directly to anyone considering ceremony.

Johnson tracked his brain activity before, during, and after each session using Kernel Flow, the neuroimaging device he spent seven years of his life building. His published results describe:

  • Decreased activity in prefrontal and premotor regions, the brain’s planning and control centers
  • Increased integration across sensory and speech networks
  • Higher entropy, a measure of how flexible and exploratory brain activity is
  • Network patterns he describes as more youthful

His default mode network, which he describes as the command center of the self, went quiet. In that quiet, sensory, auditory, and language regions began talking to each other. That pattern echoes more than a decade of research, including landmark fMRI work at Imperial College London on how Psilocybin loosens the brain’s habitual patterns.

Here the numbers and the felt experience meet.

What surprised him most, he said, wasn’t chaos. It was the opposite: openness, connection, and a childlike excitement he hadn’t felt in a very long time. His consciousness felt dialed up to a ten out of ten. Flavor exploded in his mouth. Touch arrived with awe. In his words, it felt like Psilocybin restored his perception to youthful levels, dissolving the numbness that comes with age.

Three weeks later, his baseline scan showed his brain had not fully reset. When the second dose landed, the effects built on the first rather than simply repeating, and the deepest shift appeared in his auditory, speech, and language networks. Those were the same regions lit up while his family and friends spoke to him over a live screen. The technology he built to study aging, he said, was now recording what connection felt like.

If you are curious how this kind of flexibility supports lasting change, our piece on neuroplasticity and neurogenesis goes deeper.

What Was the Most Unexpected Finding?

Nobody was looking at blood sugar.

Johnson wore a continuous glucose monitor throughout. Comparing the three days before his first dose with the three days after:

  • Mean blood glucose fell 8 percent, to 80.84 mg/dL.
  • Day-to-day glucose variability fell 11 percent.
  • Time spent above 125 mg/dL went to zero.
  • Estimated HbA1c moved from 4.7 to 4.4 percent, a 6.8 percent relative drop.

By his account, that moved his blood sugar control from the top 2 percent of the population to the top 0.2 percent, and the effect held through day three. He notes that this kind of improvement typically takes months of daily medication, while his followed a single neuroplastic event. He calls it the first documented human evidence of improved blood sugar control after Psilocybin, and stresses that it needs replication.

Two other firsts came out of the protocol.

The first was a full thermal map of a Psilocybin experience. His core body temperature rose 1.5 to 2°F at the peak, and his chest and throat warmed by about 2.5°F, something he called a thoracic heat bloom. His heat redistributed inward toward the center of his body, and the patterns across his face and upper body suggested a blend of intense joy and depth, with a subtle thread of melancholy he hadn’t expected. Around the two-and-a-half-hour mark, his heart rate climbed from 55 to 70 beats per minute.

The second was in his gut. His microbiome shifted, with several species associated with stress and insulin resistance declining, and a new beneficial species appearing that had not been there before.

What Were the Bryan Johnson Psilocybin Results, at a Glance?

Here is the Bryan Johnson Psilocybin data in one place. Every figure comes from a single participant and was reported by Johnson’s own team.

MarkerStarting pointAfter dosingReported change
Morning cortisolPersonal baseline5 days after dose 1Down 42%
DHEA-SPersonal baseline5 days after dose 1Down 45%
hs-CRP (inflammation)0.23 mg/dLBelow 0.15 mg/dL, then 0.18 mg/dL after dose 2Below detection, then 22% under baseline
Mean blood glucose3 days before3 days afterDown 8%
Glucose variability3 days before3 days afterDown 11%
Time above 125 mg/dL3 days before3 days afterWent to zero
Estimated HbA1c4.7%4.4%Down 6.8% relative
Core body temperaturePersonal baselinePeak of sessionUp 1.5 to 2°F
Brain entropyPersonal baselineDuring sessionIncreased
Bryan Johnson Psilocybin experiment: reported biomarker changes (single participant, two supervised sessions)

What Does One Person’s Data Actually Prove?

The honest answer: on its own, the Bryan Johnson Psilocybin experiment proves very little.

This is a sample size of one, in a body that was already heavily optimized, with no control group and no blinding. Johnson is clear on this himself: it is not an endorsement of magic mushrooms and not a recommendation to try them. Everything ran under direct medical supervision in a controlled environment, and his team encourages anyone curious to speak with their doctor first.

Not every marker moved in a flattering direction, either. After the second dose, his sperm motility dropped sharply, with total motile count falling 69 percent. Ninety days later, his numbers had recovered to the best he had ever recorded. We share this because the full picture matters more to us than a clean story.

What the work does offer is a direction worth following. Chronic stress, hormone dysregulation, metabolic dysfunction, and chronic inflammation are widely described as primary drivers of biological aging. All four showed measurable movement. He saw convergence across five biological systems at once: brain, hormones, metabolism, inflammation, and the microbiome. That is harder to dismiss as noise than any single number would be.

Johnson has kept exploring. In March 2026 he livestreamed a 5-MeO-DMT session, the medicine sometimes called the Everest of psychedelics, and called it one of the most underrated longevity tools. Here too, the claim sits ahead of the evidence. If you feel curious about that medicine, we share what really happens during a 5-MeO-DMT experience.

Replication is the next step, and it will take years. Both the size and the durability of these effects need independent study before anyone can responsibly claim what Psilocybin does to human aging.

We find the work valuable for a quieter reason. What Johnson’s instruments picked up in his sensory and speech networks is what guests have been telling us after ceremony for years, in words instead of numbers. Food tasting like food again. Birdsong actually landing. A child’s face looking new. There is something steadying about watching the measurements agree.

How Does a Behold Psilocybin Retreat Reflect What the Data Suggests?

Johnson’s experiment happened inside a container: medical supervision, an experienced facilitator, careful dosing, and time to rest and reflect between sessions. That container is not a detail. It is much of the point.

It is also how we hold our own Psilocybin work in Esterillos, on the Pacific coast of Costa Rica:

  • A comprehensive medical and psychological screening before any guest is accepted
  • Five nights with a gentle arc: a microdose session to begin, a first full ceremony in the evening, a full day for integration, and a final daytime ceremony
  • Experienced facilitators, and a dedicated Guest Services team member beside you from booking through departure
  • A structured preparation program that begins the moment you book, and integration support in the weeks that follow

We cannot promise anyone Johnson’s numbers. What we can offer is the kind of care that gives the medicine room to do its work.

Frequently Asked Questions

What were the Bryan Johnson Psilocybin results?

In short, his body seemed to soften. Across two supervised sessions and 249 biomarkers, his morning cortisol fell 42 percent, his inflammation dropped below what the tests could detect, his blood sugar steadied, and his brain showed patterns he described as more youthful. It is one person’s story, beautifully measured, and we hold it with both wonder and care.

Does Psilocybin lower cortisol?

It may, in the days that follow. During the experience itself, cortisol often rises as the body meets something big. Afterward, many people describe a quiet settling, and Johnson’s data showed it: his morning cortisol was 42 percent lower five days later, and the shift repeated after his second session. Every body responds in its own way, and the science here is still unfolding.

Is Psilocybin a longevity therapy?

Not yet, at least not in the eyes of science. Johnson believes it is, based on his own data, and early studies in human cells and aged mice are genuinely encouraging. But human longevity trials haven’t happened yet, and we would rather walk alongside the research honestly than run ahead of it.

Why does Psilocybin make the senses feel so vivid?

Because the part of the brain that usually holds the reins grows a little quieter. As the default mode network softens, the regions for sound, touch, taste, and language begin talking to each other more freely. Guests often tell us food tastes like food again, and birdsong finally lands. Johnson described it as his consciousness turned up to a ten.

Is Psilocybin safe for everyone?

No, and we think it matters to say that plainly. Certain heart conditions, some mental health histories, and a number of medications can make Psilocybin unsafe. That is why every guest walks through a full medical and psychological screening with us first. It exists to protect you, and sometimes the most caring answer we can give is not yet.

When is Behold’s next Psilocybin retreat?

We gather next on April 19 to 24, 2027, in Esterillos, on the Pacific coast of Costa Rica, where the jungle meets the ocean. We only operate in areas where Psilocybin is not scheduled as an illegal substance. If you feel a pull, a Discovery Call is a gentle place to begin.

Is a Psilocybin Retreat Calling You?

If something in the data stirred you, that stirring is worth listening to.

Our next Psilocybin retreat gathers April 19 – 24, 2027, in Costa Rica.

You can see how those five nights are shaped on our Costa Rica Psilocybin retreat page, or explore the medicine more broadly across our Psilocybin retreats pages. For more on the medicine itself, our Psilocybin articles are a lovely place to wander.

When you are ready, a Discovery Call is simply a conversation.

Sources

Johnson, B., “I Took Shrooms for Science,” Blueprint, 2026.

Johnson, B., “Magic Mushroom Biomarker Results,” Blueprint, 2026.

Johnson, B., “I Did Mushrooms for Science” video series, YouTube.

Kato, K. et al., “Psilocybin treatment extends cellular lifespan and improves survival of aged mice,” npj Aging, 2025.

Carhart-Harris, R. L. et al., “Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin,” Proceedings of the National Academy of Sciences, 2012.

Psychedelic Alpha, “The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream,” 2026.

About the Author

Written by the Behold Retreats editorial team. Behold Retreats curates premium, safety-first plant medicine retreats in Costa Rica, Mexico, and Portugal, with comprehensive medical screening, experienced facilitators, and integration support before and after every ceremony.